Abstract
We have previously described the critical structural determinants of anti-tumor antibodies that promote in vivo tumor targeting and antibody-dependent cellular cytotoxicity (ADCC). We now describe treatment strategies in murine models that 1) improve in vitro and in vivo ADCC, 2) dissect the relative contributions of tumor signaling perturbation and ADCC for in vivo therapeutic efficacy, and 3) identify therapy conditions that promote the induction of host-protective adaptive immunity. We also have identified tumor-intrinsic factors that sensitize tumor cells to EGFR-directed antibody therapy, using a siRNA library focused on genes functionally linked to the EGFR signaling pathway. We predict that these findings will be important for the improved efficacy of EGFR family-directed antibody therapies. Supported by CA50633, CA121033.
Citation Information: Clin Cancer Res 2010;16(7 Suppl):PL6-2
RSS Feeds